Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (171-180 of 206) with videos related to

Pageof 21
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.
Journal of Clinical Epidemiology|March 30, 2010
Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill, Loveleen Bansi, Caroline Sabin, et al.
Plos One|December 24, 2011
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008Eduard J Beck, Sundhiya Mandalia, Roshni Sangha, et al.
AIDS Patient Care and Stds|January 11, 2011
Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experienceBrendan A Larder, Andrew Revell, Joann M Mican, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Journal of Immunological Methods|June 15, 2011
Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trialsHarry Kaltsidis, Hannah Cheeseman, Jakub Kopycinski, et al.
Plos One|June 3, 2011
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006Eduard J Beck, Sundhiya Mandalia, Gary Lo, et al.
Journal of the American Heart Association|May 24, 2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) TrialJason V Baker, Shweta Sharma, Amit C Achhra, et al.
Pageof 21

Showing results (171-180 of 206) with videos related to

Sort By:
Pageof 21
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.
Journal of Clinical Epidemiology|March 30, 2010
Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill, Loveleen Bansi, Caroline Sabin, et al.
Plos One|December 24, 2011
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008Eduard J Beck, Sundhiya Mandalia, Roshni Sangha, et al.
AIDS Patient Care and Stds|January 11, 2011
Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experienceBrendan A Larder, Andrew Revell, Joann M Mican, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Journal of Immunological Methods|June 15, 2011
Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trialsHarry Kaltsidis, Hannah Cheeseman, Jakub Kopycinski, et al.
Plos One|June 3, 2011
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006Eduard J Beck, Sundhiya Mandalia, Gary Lo, et al.
Journal of the American Heart Association|May 24, 2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) TrialJason V Baker, Shweta Sharma, Amit C Achhra, et al.
Pageof 21